New Risk • Apr 24
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: kr89.8m (US$9.64m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr72m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 9.9% per year over the past 5 years. Revenue is less than US$1m (kr59k revenue, or US$6.3k). Market cap is less than US$10m (kr89.8m market cap, or US$9.64m). Annuncio • Feb 13
EXACT Therapeutics AS, Annual General Meeting, Jun 12, 2026 EXACT Therapeutics AS, Annual General Meeting, Jun 12, 2026. New Risk • Jul 27
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Norwegian stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr82m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 6.8% per year over the past 5 years. Shareholders have been substantially diluted in the past year (97% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (kr174.6m market cap, or US$17.2m). Annuncio • Jun 24
EXACT Therapeutics Announces First Patient Dosed in Phase 2 Trial in Patients with Locally Advanced Pancreatic Cancer EXACT Therapeutics announced first patient dosed in its ENACT trial. The trial is a multi-centre, open-label Phase 2 clinical trial testing the safety and efficacy of Acoustic Cluster Therapy (ACT®) in combination with standard of care (modified FOLFIRINOX chemotherapy) in first line patients with borderline resectable or unresectable locally advanced pancreatic cancer. Dosing of the first patient in the Phase 2 trial follows the announcement of positive final efficacy and safety data in the Phase 1 trial in patients with liver metastases of colorectal origin. The Phase 2 trial will enroll up to 25 patients in the U.S., U.K. and Europe, and has the ClinicalTrials.gov Identification: NCT06850623. Annuncio • Jun 13
Exact Therapeutics AS Approves Election of Following Nomination Committee Composition EXACT Therapeutics AS at its AGM held on June 13, 2025 approved to elect the following Nomination Committee composition: Svein Kvåle (Chair), Birgitte Gangmark Villmo, Sir William Castell. Annuncio • May 20
EXACT Therapeutics Announces Positive Final Results in Phase 1 ACTIVATE Trial in Liver Metastases from Colorectal Cancer EXACT Therapeutics AS announced positive final results in Phase 1 ACTIVATE trial in liver metastases from colorectal cancer. These results indicate that EXACT Therapeutics' Acoustic Cluster Therapy (ACT®?) significantly enhances the local effect of chemotherapy; In the patients who had a response to chemotherapy, ACT-treated tumours showed a significantly greater reduction in diameter compared to control tumours (-29% vs. -7%, p. The final results affirm the previously reported positive ACTIVATE outcomes and indicate the significant added efficacy of ACT with chemotherapy compared with chemotherapy alone. Among patients who responded to chemotherapy, tumor shrinkage was significantly greater with ACT and chemotherapy compared to chemotherapy alone in the same individuals (29% vs. 7%, p<0.05). New Risk • Jan 29
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 97% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 6.8% per year over the past 5 years. Shareholders have been substantially diluted in the past year (97% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (kr221.4m market cap, or US$19.6m). Annuncio • Jan 29
Cordance Medical and EXACT Therapeutics Announces Early Encouraging Data in Brain Cancer Mice Model Cordance Medical and EXACT Therapeutics announced initial positive results indicating more than a doubling (+127-145%) of the uptake of a radiopharmaceutical in brain tumors of mice inoculated with glioblastoma cancer cells, one of the most aggressive and hard-to-treat brain cancers. The increased uptake resulted from combining Exact Therapeutics' proprietary Acoustic Cluster Therapy (ACT®) with a device designed by Cordance Medical to deliver ultrasound energy non-invasively into the brain. The studies were performed at The Arctic University of Norway and University Hospital North-Norway in Tromsø by Dr. Mathias Kranz. The combination of ACT® and the device can be used in a wide range of brain diseases to potentially access large regions of the brain. The combination can stimulate bioeffects including increasing the uptake of therapeutic agents and temporarily making the blood-brain barrier more permeable in these regions. The combination of ACT® and the device may be utilized for both diagnostic and targeted therapeutic brain applications. Further experiments are ongoing to expand the early data, and the results will be submitted for publication in scientific journals. Annuncio • Jan 28
Exact Therapeutics and Cordance Medical Announce Early Encouraging Data in Brain Cancer Mice Model EXACT Therapeutics and Cordance Medical announced initial positive results indicating more than a doubling (+127-145%) of the uptake of a radiopharmaceutical in brain tumors of mice inoculated with glioblastoma cancer cells, one of the most aggressive and hard-to-treat brain cancers. The increased uptake resulted from combining Exact Therapeutics’ proprietary Acoustic Cluster Therapy (ACT®) with a device designed by Cordance Medical to deliver ultrasound energy non-invasively into the brain. The studies were performed at The Arctic University of Norway and the University Hospital of North-Norway in Tromsø by Dr. Mathias Kranz. The combination of ACT and the device may offer potential applications across a wide range of brain diseases, by enabling therapeutic access to large brain regions. The combined technologies can induce bioeffects, such as temporarily increasing blood-brain barrier permeability in targeted regions and increasing the uptake of therapeutic agents. ACT and the device may be utilized for both diagnostic and targeted therapeutic brain applications. Further experiments are ongoing to expand the early data, and the results will be submitted for publication in scientific journals. Annuncio • Jan 08
EXACT Therapeutics AS, Annual General Meeting, Jun 13, 2025 EXACT Therapeutics AS, Annual General Meeting, Jun 13, 2025. New Risk • Dec 17
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: kr107.8m (US$9.63m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 6.8% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (kr107.8m market cap, or US$9.63m). Annuncio • Aug 07
EXACT Therapeutics AS Announces Full Focus on Phase 2 Pancreatic Cancer Trial EXACT Therapeutics AS announced that it will now be focusing all clinical efforts on the upcoming Phase 2 ENACT trial in locally advanced pancreatic cancer and is stopping recruitment in the Phase 1 ACTIVATE clinical trial in cancer patients with liver metastases of colorectal origin. Previously, the Phase 1 ACTIVATE trial reported positive interim efficacy and safety data. The enrolled patients will be followed through the planned follow-up. The final results from the ACTIVATE Phase 1 trial (11 patients) will be reported after completion of independent blinded review, expected early 2025. So far, there has been no change to the previously reported excellent safety profile of PS101 in the ACTIVATE trial. New Risk • Jul 23
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Norwegian stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr47m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 14% per year over the past 5 years. Revenue is less than US$1m (kr4.5k revenue, or US$405). Minor Risks Shareholders have been diluted in the past year (6.9% increase in shares outstanding). Market cap is less than US$100m (kr255.0m market cap, or US$23.2m). New Risk • Apr 15
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m (kr453k revenue, or US$42k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (6.9% increase in shares outstanding). Market cap is less than US$100m (kr192.5m market cap, or US$17.6m). New Risk • Mar 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Norwegian stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m (kr453k revenue, or US$43k). Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Shareholders have been diluted in the past year (6.9% increase in shares outstanding). Market cap is less than US$100m (kr250.2m market cap, or US$23.5m). New Risk • Dec 22
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m (kr453k revenue, or US$44k). Minor Risks Shareholders have been diluted in the past year (6.9% increase in shares outstanding). Significant insider selling over the past 3 months (kr650k sold). Market cap is less than US$100m (kr352.9m market cap, or US$34.5m). Recent Insider Transactions • Dec 05
Chair of the Board recently sold kr300k worth of stock On the 30th of November, Anders Wold sold around 25k shares on-market at roughly kr12.00 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Anders has been a net seller over the last 12 months, reducing personal holdings by kr270k. Annuncio • Dec 02
EXACT Therapeutics AS has completed a Follow-on Equity Offering in the amount of NOK 24.999996 million. EXACT Therapeutics AS has completed a Follow-on Equity Offering in the amount of NOK 24.999996 million.
Security Name: Ordinarey Shares
Security Type: Common Stock
Securities Offered: 2,083,333
Price\Range: NOK 12
Transaction Features: Subsequent Direct Listing Annuncio • Sep 28
EXACT Therapeutics AS Announces Appointment of Caspar Foghsgaard as SVP Commercial & Business Development Effective 1 November 2023 EXACT Therapeutics AS announced that Caspar Foghsgaard is joining the company as Senior Vice President Commercial and Business Development, effective 1 November 2023. Caspar Foghsgaard joins Exact Therapeutics from Nykode Therapeutics where his latest role was as Sr. Director Special Projects and part of the extended leadership team. He joined Nykode in 2018 and have been closely involved in Nykode’s transformation from a small biotech to a leading company at Oslo Stock Exchange. Prior to his role as Sr. Director Special Projects, he was heading Nykode’s business development activities as Director Business Development. Other previous employers include Arcus where he was responsible for business development in the spirits division and part of the divisional management, and Elopak as Program Director Strategy. In addition, he has held various business development and strategy positions including with Novozymes in Denmark, U.S. and U.K. Annuncio • Sep 27
EXACT Therapeutics Announces Positive Clinical Results from the Activate Phase I Dose Escalation EXACT THERAPEUTICS AS announced positive safety and anticancer activity results from the dose escalation part of the ACTIVATE trial. The data will be presented at a medical conference in early 2024. Eight patients were enrolled into the dose escalation part of the study. The results suggest that ACT treatment in combination with FOLFOX or FOLFIRI is well tolerated without unexpected acute or delayed side effects of the ACT treatment or worsening of side effects of the chemotherapy. Positive anticancer responses have been seen in all but one of the evaluable patients in this hard-to-treat patient population, showing that the ACT treatment can enhance anticancer response to Standard of Care chemotherapy. Annuncio • Aug 08
EXACT Therapeutics Completes the Dose Escalation Part of ACTIVATE Study EXACT Therapeutics AS announced that the dose escalation part of the ACTIVATE study is completed. This part of the study enrolled 8 patients, with 6 patients eligible for evaluation. The study is conducted at the Institute of Cancer Research (ICR), Royal Marsden Hospital, London with Professor Udai Banerji as the principal investigator. A presentation of the safety and efficacy findings will be released when the full results are available. The study Trial Monitoring Committee reviewed the safety data from the dose escalation and approved initiation of the dose expansion part of the ACTIVate study. The dose expansion is designed to determine the dose level for further development of ACT and expand the safety and efficacy data with 12 to 20 patients with metastatic colorectal cancer. All necessary approvals have already been awarded by the UK MHRA, as reported on July 31, and enrolment will now commence. Annuncio • Aug 01
EXACT Therapeutics AS Receives Regulatory Approval to Start the Dose Expansion Part of ACTIVATE Study EXACT THERAPEUTICS AS announced that the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has awarded all necessary approvals to start the dose expansion part of the ACTIVATE study. This part of the ACTIVATE study is designed to determine the dose level for further development and expand the safety and efficacy data of ACT in patients with metastatic colorectal cancer. 12 to 20 patients are planned to be enrolled into the dose expansion part of the ACTIVATE study. Board Change • Jun 22
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Chair of the Board Anders Wold was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Annuncio • Jun 10
EXACT Therapeutics AS Announces Management Changes EXACT Therapeutics AS at its Annual General Meeting held on June 9, 2023, announced Jean-Michel Cosséry is not seeking re-election as board member. In accordance with the Nomination Committee's proposal, the following Nomination Committee composition was made: Leiv Askvig (Chair); Dag Strømme; Birgitte Gangmark Villmo and Svein Kvåle. Board Change • Apr 21
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Chair of the Board Anders Wold was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Annuncio • Feb 03
Exact Therapeutics Receives Regulatory Approval to Reopen the Activate Clinical Trial On February 2, 2023, EXACT Therapeutics AS announced that the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has approved reopening of the clinical phase I ACTIVATE trial. As communicated in a press release of 8 March 2022, EXACT-Tx received a request from the MHRA for an additional submission and approval of medical device documentation associated to the protocol amendment filed with the ACTIVATE phase I clinical trial. EXACT-Tx responded to the request and has now received MHRA’s approval on both the medical device documentation and the amended protocol. The approvals were made without objections. For EXACT-Tx, this mean that the ACTIVATE phase I trial will be reopened and additional patients will be recruited for the trial. So far, there have been seven patients enrolled in the study with five patients’ data being evaluable for the study endpoints. Several valuable and encouraging insights have been gained from this first cohort of treated patients. Board Change • Jan 25
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Chair of the Board Anders Wold was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Dec 22
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Chair of the Board Anders Wold was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Dec 02
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Chair of the Board Anders Wold was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Nov 17
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Chair of the Board Anders Wold was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Sep 14
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Chair of the Board Anders Wold was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Jul 22
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Chair of the Board Anders Wold was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Jun 08
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Anders Wold was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Apr 29
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Director Anders Wold was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Feb 25
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Director Anders Wold was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • Dec 07
Executive Chairperson recently bought kr71k worth of stock On the 3rd of December, Masha P. Strømme bought around 4k shares on-market at roughly kr16.59 per share. This was the largest purchase by an insider in the last 3 months. Masha P. has been a buyer over the last 12 months, purchasing a net total of kr206k worth in shares. Executive Departure • Dec 06
Director Hans Klouman has left the company On the 3rd of December, Hans Klouman's tenure as Director ended. As of September 2021, Hans still personally held 399.75k shares (kr8.3m worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model. Recent Insider Transactions • Jun 08
Deputy Chairperson recently bought kr208k worth of stock On the 4th of June, William Castell bought around 10k shares on-market at roughly kr20.80 per share. This was the largest purchase by an insider in the last 3 months. This was William's only on-market trade for the last 12 months. Executive Departure • Feb 03
Chief Financial Officer has left the company On the 31st of January, Stig Pettersen's tenure in the role of Chief Financial Officer ended. As of September 2020, Stig personally held 30.00k shares (kr1.0m worth at the time). Stig is the only executive to leave the company over the last 12 months. Annuncio • Jan 31
EXACT Therapeutics AS Announces Executive Changes EXACT THERAPEUTICS AS announced that the company’s CFO Stig Jarle Pettersen, engaged as a part time consultant via his company CFO For Hire AS, will leave the company on January 31st 2021 at the end of his contracted period. The process of hiring a full time CFO is ongoing and Ole Fegth of Abaci AS will assume CFO responsibilities for the company until ad interim. Annuncio • Jan 22
Exact Therapeutics Announces Innovative Probe Development Collaboration with GE Healthcare EXACT THERAPEUTICS AS announced a collaboration with GE Healthcare to develop an innovative ultrasound probe to be used in forthcoming studies using Acoustic Cluster Therapy (ACT®) across multiple disease conditions. ACT® is a proprietary formulation consisting of microbubbles and microdroplets that are activated through the application of ultrasound with the consequent increase in targeted delivery of a co-administered therapeutic agent. ACT® is supported by a strong and broad preclinical package demonstrating therapeutic enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as well as controlled blood-brain barrier opening. Currently ACT® is being evaluated in the international ACTIVATE Phase I clinical trial in patients with metastatic colorectal and pancreatic cancer at the Royal Marsden Hospital in London. Is New 90 Day High Low • Dec 03
New 90-day low: kr25.50 The company is down 29% from its price of kr36.00 on 04 September 2020. The Norwegian market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 27% over the same period. Is New 90 Day High Low • Oct 15
New 90-day low: kr31.50 The company is down 7.0% from its price of kr34.02 on 17 July 2020. The Norwegian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 39% over the same period. Annuncio • Sep 09
EXACT Therapeutics AS has completed an IPO in the amount of NOK 155.010604 million. EXACT Therapeutics AS has completed an IPO in the amount of NOK 155.010604 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 29,804
Price\Range: NOK 5201
Transaction Features: Direct Listing; Sponsor Backed Offering Annuncio • Aug 23
EXACT Therapeutics AS to Report Fiscal Year 2019 Results on Apr 29, 2021 EXACT Therapeutics AS announced that they will report fiscal year 2019 results on Apr 29, 2021